

FIGURE 1A




FIGURE 1B




FIGURE 1C




FIGURE 1D




FIGURE 2A

MDA-MB-231 Human breast cancer model
(Subcutaneous, 24 Hours of Treatment)




FIGURE 2B
U87 Human glioblastoma model
(Intracranial, Long term Treatment)




FIGURE 2C


Wound Healing
(12 Hours of Treatment)

FIGURE 2D




FIGURE 3





FIGURE 4A



FIGURES 4B-4C




Figure 4B

Figure 4C

FIGURE 4D

MDA-MB-231 tumor sections (72 hours post-treatment)






FIGURE 4E



14/24

FIGURE 5A




FIGURE 5B




FIGURE 6





FIGURE 7



Effect of bevacizumab on VDV expression in human tumor Biopsies




FIGURE 8A





FIGURE 8B





FIGURE 8C



Spearman's correlation coefficient

FIGURE 8D





FIGURE 9A




FIGURE 9B





FIGURE 9C

